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Background: Two new rhodopsin mutations associated with the rare form sector retinitis 
pigmentosa (RP) have been found. 
Results: Characterization of both rhodopsin mutant proteins shows different progression 
correlating with a different behavior of rhodopsin upon light exposure. 
Conclusions: Light plays an important role in triggering sector RP. 
Significance: Other mechanisms, in addition to protein misfolding, underlie GPCR dysfunction in 
pathological processes. 
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Retinitis pigmentosa (RP) is a group of genetically and clinically heterogeneous inherited 
degenerative retinopathies caused by abnormalities of photoreceptors or retinal pigment epithelium 
in the retina leading to progressive sight loss. Rhodopsin is the prototypical G-protein-coupled 
receptor located in the vertebrate retina and responsible for dim light vision. Here, novel M39R and 
N55K variants were identified as causing an intriguing sector phenotype of RP in affected patients, 
with selective degeneration in the inferior retina. In order to gain insights into the molecular aspects 
associated with this sector RP phenotype, whose molecular  mechanism remains elusive, the 
mutations were constructed by site-directed mutagenesis, expressed in heterologous systems and 
studied by biochemical, spectroscopic and functional assays. M39R and N55K opsins had variable 
degrees of chromophore regeneration when compared to WT opsin, but showed no gross 
structural misfolding or altered trafficking. M39R showed a faster rate for transducin activation than 
WT rhodopsin with a faster metarhodopsinII decay, whereas N55K presented a reduced activation 
rate and an altered photobleaching pattern. N55K also showed an altered retinal release from the 
opsin binding pocket upon light exposure, affecting its optimal functional response. Our data 
suggest that these sector RP mutations cause different protein phenotypes which may be related 
to their different clinical progression. Overall, these findings illuminate the molecular mechanisms 
of sector RP associated with rhodopsin mutations.   
 
RP refers to a group of inherited visual diseases that cause retinal degeneration and its 
incidence is around one of 4000 people (1). In the initial phase of the condition, RP patients have 
impaired dark adaptation and suffer from night blindness. Progression of the disease involves 
appearance of so-called tunnel vision, lack of outer lateral vision, the half-peripheral visual field is 
reduced to 30º-50°, and it can be accompanied by a decrease of the visual acuity. At later stages, 
signs include attenuated retinal vessels, and intraretinal bone pigment distributed circumferentially 
around the mid periphery in the fundus; myopia and astigmatism are also common (2).  
Rhodopsin (Rh) is the prototypical member of the G-protein coupled receptor (GPCR) 
superfamily of membrane proteins, which includes over 900 members (3). The structures of 
several members of this superfamily have been resolved in the past decade using X-ray 
crystallography (4,5). Rh has been crystallized in various states, such as the dark-state form, the 
ligand-free form opsin structure, and the G protein-interacting conformation of opsin (6-8). 
Rh is the light sensitive protein of the rod cell in the retina and is concentrated in the discs of the 
rod outer segment (9,10). In its basal resting state it consists of a polypeptide chain, opsin, and its 
cognate chromophore, the vitamin A aldehyde derivative 11-cis-retinal, which acts as an inverse 
agonist preventing G-protein activation in the dark (3,11). The retinal chromophore is responsible 
for light absorption in the visual process (12) and, upon photon capture, it isomerizes to its all-trans 
configuration yielding the active Rh photointermediate metarhodopsin II (MetaII) capable of binding 
and activating the G protein transducin (Gt) (13-15).  
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Mutations in the opsin gene are the most common cause of dominant RP. The large number of 
mutations and their different location along the polypeptide chain indicate a highly sophisticated 
arrangement of physicochemical interactions in the three dimensional structure of the native 
molecule. Although protein misfolding or altered trafficking are considered to be the major 
biochemical features of many RP mutations in Rh (16-19), some mutations do not induce major 
structural defects (20,21), but cause changes in G protein binding and activation (22,23), or the 
formation of altered photointermediates (24,25), among other phenotypes (17,25-28). Sector RP is 
an atypical form of RP, ranging from stationary to slowly progressive evolution of the retinal 
degenerative pattern, characterized by regional areas of bone spicule pigmentation, subnormal 
electroretinogram and visual-field defects, usually in the inferior quadrant of the retina (29,30).  
It is important to obtain detailed knowledge of the characteristics of mutant proteins and to 
correlate the molecular defect observed with the clinical phenotype of the affected RP patients. For 
this purpose, we expressed, purified and characterized recombinant receptors containing 
mutations at amino acid N55 and M39, initially associated with sector RP, in order to determine the 
effect of these mutations on Rh stability and functionality. Residue N551.50 is part of the conserved 
GX3N motif (31,32) in the first transmembrane helix (TM) of the receptor and has been proposed to 
be involved in a net of conserved allosteric interactions important for signal transduction (33). 
M391.34 is also located at the first TM, in one of the sites of the proposed retinal channel, where 
retinal can enter the protein and leave upon Schiff base (SB) breakage after photoactivation (34). 
We found that these two mutants show similar structural instability in the dark and significantly 
different photobleaching and G-protein activation responses. In particular, N55K shows a clear 
altered response to illumination in contrast to M39R behaviour. These differences at the molecular 
level may be correlated with the observed different clinical progressions for the two mutations.  
 
Experimental procedures 
 
Patients and clinical data- Patients and families were recruited from the inherited retinal clinics 
at Moorfields Eye Hospital as part of a larger study. Informed consent was obtained from all 
participants and all investigations were conducted in accordance with the principles of the 
Declaration of Helsinki. Institutional Review Board (IRB)/Ethics Committee approval was obtained 
from the Moorfields Eye Hospital Local Ethics Committee.  
Patients and families with specific mutations in the RHO gene (RP4) were included in this study. 
Ophthalmological examination included best corrected visual acuity testing using Snellen charts, 
dilated fundus examination, color fundus photography (TRC-50IA; Topcon, Tokyo, Japan), spectral 
domain Optical Coherence Tomography (OCT) and fundus autofluorescence imaging (FAF). The 
Spectralis HRA+OCT with viewing module version 5.1.2.0 (Heidelberg Engineering, Heidelberg, 
Germany) was used to acquire tomographs. FAF images were acquired using the HRA2 and 
Spectralis HRA+OCT (encompasing a 30° × 30° and/or a 55° × 55° field; Heidelberg Engineering). 
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Materials- All chemicals were purchased from either Fisher Scientific (Madrid, Spain) or Sigma-
Aldrich (St. Louis, MO, USA) except where stated. 11-cis-Retinal was kindly provided by Dr. R. 
Crouch and the National Eye Institute, National Institute of Health (USA). Purified Rh-1D4 was 
obtained from Cell Essentials (Boston, MA USA) and was coupled to CNBr-activated Sepharose 
4B Fast Flow (Amersham Biosciences), secondary HRP conjugated goat antibody was provided by 
Santa Cruz Biotechnology (Heidelberg, Germany). n-Dodecyl-D-maltoside (DM) was purchased 
from Affimetrix (Maumee, OH, USA). The nanomer peptide corresponding to the last 9 amino acids 
of Rh was synthesized by Serveis Cientificotècnics (Universitat de Barcelona, Barcelona, Spain). 
Site-directed mutagenesis was performed by using Agilent Pfu polymerase and DpnI restriction 
enzyme and following QuickChange mutagenesis instructions (Agilent, Santa Clara, CA, USA). 
EndoH (cat numb. P0702L) and PNGaseF (P0704L) were from NEB (Hitchen, UK). 
Cell culture materials- COS-1 cells were purchased from the American Type Culture Collection 
(Manassas, VA, USA), and SK-N-SH human Caucasian neuroblastoma cells from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK). Tissue culture medium were provided from 
PAA (Austria) or Sigma Aldrich, antibiotics and Serum from Sigma-Aldrich (St. Louis, MO, USA), 
OPTIMEM Reduced Serum Media from Life Technologies (Madrid, Spain) and the polymer used 
for transfection, polyethylenimine 25 kDa (PEI), from Polysciences (Warrington, PA, USA). For 
cellular localization, the primary antibodies Rh-1D4 and Rh-4D2 against rod opsin were a gift from 
Robert Molday (Department of Biochemistry and Molecular Biology, University of British Columbia, 
Vancouver, Canada). Rabbit ployclonal anti-BiP Anti-GRP78/BiP (GL-19) (cat. number G8918) 
was from Sigma. Goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594 secondary 
antibodies conjugated IgGs, Lipofectamine and Plus reagent were purchased from Invitrogen 
(Paisley, United Kingdom). Goat anti-mouse secondary antibody conjugated with horseradish 
peroxidase was from Pierce. 
Buffers- Solutions used are defined as follows: Buffer A (137 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, and 8 mM Na2HPO4, pH 7.5), Buffer C (0.05% DM in buffer A, pH 7.5), and Buffer Gt (25 
mM Tris pH 7.5, 100 mM NaCl, 5 mM magnesium acetate, 2.5 mM DTT, and 5µM [S35]GTPγS 
(1.78 Ci/mmol)). 
Construction, expression, and purification of mutant Rh- Opsin mutants were constructed with a 
site-directed mutagenesis kit (QuikChange, Stratagene) using a synthetic bovine opsin gene as a 
template (36). The expression and purification of the visual receptors were performed as previously 
described (37). Briefly, plasmids encoding the WT or mutant Rh genes were transfected into five 
COS-1 cells plates at 85% confluence, by using PEI with 30 µg of plasmid DNA per 145-cm plate. 
Cells were harvested 48–60 h after transfection, and pigments were reconstituted with 10 µM 11-
cis-retinal in intact cells and then solubilized with 1% (w/v) DM in Buffer A. After centrifugation, the 
supernatant was incubated with a Sepharose 4B coupled to the Rh-1D4 antibody. The resin was 
washed with buffer C and pigments were subsequently eluted with the same buffer but containing 
100 µM nonamer peptide.  
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Subcellular localization- SK-N-SH cells were maintained and transfected as described (35). 24 h 
after transfection, cells were fixed with 4% paraformaldehyde for 15 min and permeabilized in 0.5% 
Triton X-100 for 10 min. Nonspecific binding was blocked using blocking buffer (3% BSA and 10% 
serum of the secondary antibodies species in PBS) for 1 h. Rh-1D4 primary antibody (1:5000), 
anti-BiP (1:100) or Rh-4D2 primary antibody (1:100) in blocking buffer was added for 1 h. 
Secondary Alexa Fluor 488 or 594 were used at 1:1000 in blocking buffer for 1 h. Images were 
taken using a Carl Zeiss LSM 710 laser-scanning confocal microscope. The images were exported 
from LSM Browser and prepared using Adobe Photoshop and Illustrator CS4. Cell morphology 
studies scored the predominant localization of rod opsin on the plasma membrane (PM), or strong 
overlap with an endoplasmic reticulum (ER) marker, as a percentage of total transfected cells. Four 
fields of approximately 100 cells were counted for each condition. 
Western blotting and glycosidase digestion- SK-N-SH transfected cells were lysed for 15 min at 
4°C in PBS buffer containing 1% DM and 2% protease inhibitor cocktail in PBS. Cell lysates were 
centrifuged for 15 min at 12,000 x g and at 4ºC. For deglycosylation reactions, 10 μg total protein 
in DM soluble cell lysate was digested with EndoH or PNGase F for 2 h at 37°C. 10 µg total protein 
was added to 2x Laemmli loading buffer before being subjected to SDS-PAGE and Western 
blotting. For opsin immunodetection, Rh- 1D4 was used at 1:1500 and goat anti-mouse HRP 
(Pierce) was used at 1:50000 in 5% (w/v) Marvel Milk in PBS with 0.1 % (v/v) Tween buffer (PBS-
T).  
Absorbance and fluorescence spectroscopy instrumentation- All measurements were made on 
a Cary 100Bio spectrophotometer (Varian, Australia), equipped with water-jacketed cuvette holders 
connected to a circulating water bath. Temperature was controlled by a Peltier accessory 
connected to the spectrophotometer. All spectra were recorded in the 250nm–650 nm range with a 
bandwidth of 2 mm, a response time of 0.1 s, and a scan speed of 300 nm/min. The spectral ratio, 
which was used as a measure of pigment yield and stability, is defined as Absorbance at λ280nm 
divided by Absorbance at the visible λmax value. All fluorescence assays were performed by using 
a Photon Technologies QM-1 steady-state fluorescence spectrophotometer (PTI Technologies, 
Birmingham, NJ, USA). Sample temperature was controlled with a cuvette holder Peltier accessory 
TLC 50 (Quantum Northwest, Liberty Lake, WA, USA) connected to a hybrid liquid coolant system 
Reserator XT (Zalman, Garden Grove, CA, USA). All fluorescence spectra were carried out by 
exciting the samples for 2 s at λ295 nm and a bandwidth slit of 0.5 nm and blocking the excitation 
beam for 28 s with a beam shutter to avoid photobleaching of the sample (38). Tryptophan 
emission was monitored at λ330 nm and a bandwidth slit of 10 nm. 
Spectral characterization of purified Rh- 
Samples were bleached with a 150-watt power source equipped with an optic fiber guide and using 
a 495-nm cut-off filter. Dark-adapted pigments were illuminated for 30 s to ensure complete 
photoconversion to 380-nm absorbing species. Acidification was carried out, immediately after 
photobleaching, by the addition of H2SO4 2N. 
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Thermal bleaching assay- Rh thermal stability was monitored as previously described (39). 
Briefly, Rh bleaching rates, in the dark, were obtained by monitoring the decrease of absorbance at 
λmax of the visible spectral band as a function of time at 48 °C. Spectra were recorded every 2.5 
min and half-life times were determined by fitting the experimental data to single-exponential 
curves using Sigma Plot version 11.0 (Systat Software, Chicago, IL, USA). 
Hydroxylamine assay- A solution of hydroxylamine hydrochloride 1M, adjusted to pH 7, was 
added to dark-adapted samples in Buffer C (final concentration of 50 mM), and successive spectra 
were recorded every 2.5 min to monitor the loss of pigment (Amax) and formation of retinal oxime 
(A365 nm). Reactions were carried out in the dark at 20°C (37). Initial velocity was determined by 
fitting the experimental data to either a single-exponential curves or a linear plot using Sigma Plot 
version 11.0 (Systat Software). 
MetaII decay measurements- The MetaII active conformation decay process was followed in 
real time by fluorescence spectroscopy (38). Briefly, 0.5 µM Rh in Buffer C was kept at 20°C for 10 
min and illuminated for 30 s. The t1⁄2 values of Trp fluorescence increase, due to retinal release, 
were determined by fitting the experimental data to a single-exponential curve using Sigma Plot 
version 11.0 (Systat Software, Inc., Chicago, IL, USA).  
Gt activation assay- G protein activation was determined in COS-1 cell membranes, prepared 
as previously described (37) and the ability of opsin and Rh to activate Gt was monitored with a 
radionucleotide filter binding assay by measuring the uptake of [S35]GTPγS by Gt purified from 
bovine retinas. The assays were performed by mixing 10 nM Rh or opsin in membranes with 500 
nM Gt in Gt buffer at room temperature. Reactions were initiated by the addition of Rh or opsin in 
the dark, and samples were filtrated after different incubation times, either in the dark or after 
illumination, to determine the amount of bound [S35]GTPγS. 
 
Results 
 
Clinical Findings- Of 73 unrelated families presenting to the inherited retinal disease clinics at 
Moorfields with retinal degeneration, in which RHO was the established causative gene, three 
families were found to harbour the variant p.N55K. Clinical data were available on five affected 
individuals from these three families. In family GC18466, the female proband first noticed 
nyctalopia in the 30s and was diagnosed with RP at age 35. Visual acuities were normal when 
measured at age 45 years. A de novo mutation was assumed because neither parent had 
symptoms, nor did they harbour the mutation. The fundus and OCT findings for this patient are 
shown in Fig. 1A-D, G-H, and I-J. Two from three children were found presymptomatically to have 
inferior retinal pigmentation suggestive of RP at ages 13 and 14 years. In family GC16563, the 26 
year old female proband was examined by an optometrist following the incidental finding of retinal 
signs in her mother. Despite inferior retinal pigmentation, no symptoms had developed up until the 
last review at age 39 years (Fig. 1E-F). Electroretinography ISCEV standard at this age was 
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normal. In the third family, GC17079, a female patient at the age of 37 years had night-blindness 
and field loss, the latter enough to fail the UK driving standard. Visual acuities were 6/9 right, 6/5 
left. There was a family history compatible with autosomal dominant segregation but no other 
relatives were examined. 
Of the 73 unrelated RHO families, 6 families were identified with p.M39R heterozygous 
mutations (GC97, 109, 414, 1379, 4740 and 19172). All of them consistently showed an inferior 
hemisphere that was more affected than the superior. The eye fundus autofluorescence images for 
patients from some of these families are shown in Fig. 2. In contrast to p.N55K, however, the 
retinal degeneration was more severe and progressed to the superior retina with age (Fig 2). 
Molecular modelling of the RP mutants- 
The repertoire of Rh crystal structures (7,8,40-43) suggest the existence of a channel between 
TMs 1 and 7 that retinal uses to entry/exit its binding cavity (34). M39 lies at the mouth of this 
channel, where the crystal structures revealed the presence of fatty acids, lipids and detergent 
molecules (Fig. 3A), supporting the hypothesis that this region might accommodate hydrophobic 
retinal in an intermediate step. Fig. 3B shows that F293, adjacent to M39, exhibits a conformational 
change upon receptor activation. Specifically, in the crystal structures representing the inactive 
states (Fig. 3B, orange cartoon), F293 is buried within the binding pocket and closes the channel 
by interacting with L40, whereas in those representing active structures (Fig. 3B, red cartoon), 
F293 has moved towards the membrane exposed face of TM1 and interacts with Y43 (Fig. 3B). 
This conformational change is accompanied by a parallel shift of TMs 6 and 7 towards TM1. 
Consequently, the presence of a positively charged residue, such as R39, nearby this network, 
would potentially alter the exit/entry of retinal through the ligand channel, and it may also affect the 
conformational changes involving helical motions ensuing receptor photoactivation. 
Three highly conserved residues, throughout the GPCRs superfamily, at the cytoplasmic side of 
the receptor, N551.50 (98%), D832.50 (92%) and N3027.49 (77%) define a region with intimate contact 
between TMs 1, 2 and 7, which involve also various highly conserved water molecules (44) (Fig. 
3C). In the N55K substitution, the Lys side-chain would interfere with these contacts and form a 
salt bridge with D832.50. 
On the other hand, our molecular models suggest that the M39R substitution may alter the 
TM1-TM7 interface and the network of interactions between TMs 1, 6 and 7, suggesting problems 
on receptor stability, and the rate of both Gt activation and retinal release, due to the location of 
M39R in the proposed entry/exit retinal channel (34). 
Subcellular localization of RP mutants in SK-N-SH cells- The heterologous expression of rod 
opsin in cell culture can be used to monitor protein biogenesis, traffic and facilitate protein 
purification for functional studies. We used SK-N-SH neuroblastoma cells to study the biogenesis, 
degradation, aggregation and traffic of WT and mutant forms, as this cell line has been used 
extensively in the past (e.g. (37)). WT rod opsin was mainly localized on the PM (94% of 
transfected cells) and did not overlap with the ER marker BiP (Fig. 4A and C). Occasionally WT rod 
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opsin was predominantly retained in the ER (5% of cells) or formed intracellular inclusions (3% of 
cells) (Fig. 4A and C). The M39R and N55K amino acid substitutions in rod opsin did not have a 
major effect on traffic in SK-N-SH cells (Fig. 4A). Both mutants were localized to the PM in the 
majority of cells (88% and 80% respectively) and only a few cells showed predominant retention in 
the ER and overlap with BiP staining or inclusion formation (Fig. 4A and C). The traffic of WT, 
N55K and M39R rod opsin to the PM was confirmed by staining non-permeabilized transfected SK-
N-SH cells with the Rh antibody 4D2, which recognizes an extracellular epitope (Fig. 4B). The 
electrophoretic mobility of the mutant proteins on Western blotting was similar to WT rod opsin 
(Fig. 4D); but the expression level was generally reduced. Digestion of cell lysates with the 
glycosidase EndoH showed that, like WT, most of the N55K and M39R rod opsin protein was 
EndoH resistant and therefore had trafficked beyond the ER (Fig. 4D). 
UV-vis spectral characterization of purified mutants- The RP mutant opsins were purified and 
their UV-visible spectra investigated (Fig. 5). N55K and M39R were purified at a lower yield when 
compared to WT, and they also had a ratio A280/Amax of 5.4 and 6, approximately 2.2 and 2.4-
fold higher when compared to the WT ratio, respectively (Table 1). This could indicate folding 
problems in these mutants that may not allow complete regeneration with 11-cis-retinal. The dark 
spectra of N55K showed a blue shift of 3 nm in the visible absorbance band when compared to 
that of the WT. Upon illumination, the N55K spectrum also showed a specific behavior, without a 
complete conversion of the visible band to the 380-nm absorbing species. This remaining band, 
observed upon illumination, had a similar visible wavelength maximum as the dark pigment, blue-
shifted only 3 nm, suggesting conversion to a photointermediate with a retinal binding pocket 
similar to the dark pigment, including the presence of a protonated SB linkage. This behavior is 
different from other RP mutants, such as G51V and G89D, that also showed a blue-shifted 
photointermediate, possibly reflecting changes in the retinal binding pocket (24,45). The M39R 
mutant had photobleaching behavior similar to that of the WT protein (compare insets in Fig. 5).  
Thermal and chemical stability in the dark- The chemical reagent hydroxylamine, added in the 
dark, decreased the visible maximal absorbance, especially in the case of N55K. Here, the initial 
rate of the hydroxylamine-induced bleaching process was about 50-fold faster than that of WT Rh 
(Table 1 and Fig. 6A), suggesting that the SB in this mutant is more exposed to the environment so 
the reagent can enter, break the SB and sequester the retinal from the binding pocket. 
Hydroxylamine also affected the chemical stability of M39R mutant but to a lesser extent than 
N55K. Thermal bleaching was studied at 48ºC, by monitoring the decrease of absorbance at the 
visible λmax over time. Both RP mutants were unstable in the dark-state (Table 1 and Fig. 6B). In 
order to improve protein stability, 1,2-didocosahexaenoylsn-glycero-3-phosphocholine (DDHA-PC) 
lipid was used, previously shown to increase Rh stability (46), but it did not help to stabilize N55K, 
when compared to Rh from rod outer segments (data not shown).  
MetaII stability- The stability of the active state of purified Rh was measured by monitoring the 
fluorescence increase upon illumination (Fig. 7). MetaII stability t1/2 of N55K mutant was similar to 
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that of WT Rh, showing that this mutation does not affect initial retinal release upon illumination, 
whereas for the M39R mutant the release occurred faster (t1/2= 10.8 min). When a fluorescence 
plateau was reached, hydroxylamine was added to test whether there was still retinal remaining in 
the binding pocket. Strikingly, N55K reached a plateau at lower fluorescence intensity and showed 
an additional increase in Trp fluorescence emission, upon hydroxylamine addition to the sample, 
reflecting the presence of residual retinal in the binding pocket for a long time after bleaching (Fig. 
7C). In order to determine if this could be a differential feature of sector RP mutants, retinal release 
was compared to that of the G51V RP mutant, position G51 is located one helical turn below N55 
and G51V also showed a different photobleaching behavior when compared to WT similar to N55K 
(45). In this case, however, the G51V MetaII assay showed a similar behavior to WT (data not 
shown).  
Gt activation for WT and mutants- Gt activation by Rh and opsin forms was monitored by using 
a GTPγS35 binding assay where the protein was incubated in a mixture containing the G-protein. 
The amount of GTPγS35 bound was determined by a radioactive binding assay (37). The opsin 
form (i.e. with no retinal) was used in order to determine whether the mutations caused constitutive 
activity. We observed that these mutations do not activate Gt in the absence of the ligand and thus 
they are not constitutively active (Fig. 8). Photoactivated mutant Rh activated Gt but with altered 
kinetics. Compared to the WT, M39R activated Gt at a faster rate, whereas N55K activated the G 
protein at a slower rate, 3.4 and 0.3-fold respectively (Table 1). The N55K result is compatible with 
the proposed importance of the conserved N1.50 position in G-protein activation (47-49).  
 
Discussion 
 
Understanding the molecular mechanism(s) underlying retinal degeneration is the first step 
towards finding an efficient treatment for RP. Here, we analyzed the consequences on the stability 
and functionality of Rh caused by the two newly identified RP mutations, M39R and N55K, located 
in the first TM of the receptor. Spectral characterization showed that M39R and N55K behave 
differently than the WT showing decreased chromophoric visible bands than the WT protein after 
purification in detergent solution. In spite of the fact that the pattern observed in our spectra could 
be compatible with some sort of protein misfolding, as previously reported for other RP mutations, 
such as T58R (50), the results obtained from the cellular localization clearly indicate that these 
mutants trafficked to the PM at a similar level to WT opsin, suggesting that these mutations do not 
significantly alter the folding of Rh in the ER of cell culture systems. Moreover, Western blot 
analysis of these mutant proteins showed a slightly different mobility and lower level of expression 
when compared to the WT, which may reflect differences in the degradation rate and/or 
glycosylation pattern (Fig. 4C). However, digestion with the glycosidase EndoH, which digests ER 
resident glycoproteins, confirmed that most of the N55K and M39R mutant protein trafficked 
normally. Therefore, if the lower expression levels are due to enhanced degradation this must be 
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efficient, as the mutant proteins did not accumulate in the ER.  Taking all this evidence into 
account, we suggest that the decrease in the level of chromophore present in the purified samples 
is potentially due to protein instability during the purification process, rather than an ER folding 
problem. Because chromophore stability of these two mutants was 90% lower than that of WT 
when treated at 48ºC (Table 1), but they still reached the PM in over 80% of cells (in contrast with 
the ER retention levels seen as one of the key features for class II mutants (28)), both mutants are 
more consistent with a class IV phenotype of near normal native folding but with inherent structural 
instability (20). The crystal structures suggest that the effects of M39R on Rh could be related to 
the involvement of the residue in a proposed entry/exit channel for retinal between TMs 1 and 7 
(34).  
In the case of the N55K substitution, the mutation at the conserved N1.50 residue affected retinal 
release during the MetaII decay. Addition of hydroxylamine to the sample, after the fluorescence 
signal had reached a plateau, caused further release of retinal, indicating that some retinal was still 
present inside the protein a long time after photobleaching. This retinal trapping would undoubtedly 
alter the visual cycle, affecting the normal retinal turnover rate (51). This behavior was not detected 
for the G51V RP mutant (45) located only one helix turn away from N55, which also shows a 
different photobleaching behavior when compared to WT Rh. In this case, the similar retinal 
release pattern to WT suggests that the retinal trapping found in the N55K mutant may be a 
distinctive feature of this form of sector RP. Our molecular modelling results suggest that the Lys 
residue interferes in the network between TMs 1, 2 and 7, due to the proximity of N55, D83, and 
N302, including water molecules (44). Additionally, Fourier-transform infrared difference spectra 
experiments indicated that D832.50 should be protonated (52), which would be affected by the 
introduction of Lys in this environment. 
The molecular differences observed for the N55K and M39R mutated proteins can be 
associated with the physico-chemical nature of the introduced amino acid residue as a result of the 
mutation. Both mutations are located at the same helix (TM1) of Rh, and both introduce positively 
charged amino acids of a similar volume. However, the N55K substitution appears to have a 
specific behavior. Interestingly, another mutation to Lys in the TM domain of Rh, M207K, was 
shown to have an unusual autosomal dominant retinal phenotype characterized by a 
heterogeneous distribution (53). It is possible that mutations introducing a Lys, at the 
transmembrane core of Rh, cause unusual phenotypes as a result of affecting the entry/exit paths 
of the retinal chromophore after isomerization and SB hydrolysis.  
The intrinsic structural features of the receptor-bound chromophore, in some Rh RP mutants, 
could result in differences in keeping the retinal in its binding pocket and altering its release 
mechanism. And this could be the starting cause of the retinal degeneration process. Thus, the 
presence of unstable free opsin proteins, either in the dark or at different stages of the 
photoactivation process, could result in protein aggregation and ultimately in cell death. The 
presence of fully functional Rh is important for maintaining healthy photoreceptor cells. Rh knock-
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out mice have been reported to be unable to generate photoreceptor rod outer segments (54). In 
the case of N55K, a critical factor, in addition to its inherent instability, is the altered behavior upon 
illumination (and associated altered retinal release) that could affect the Rh photocycle disrupting 
normal retinal accessibility and protein turnover.  
Besides the structural consequences of these mutations, the big question is why the affected 
region is restricted to a specific part of the retina when the Rh mutation is present all over the 
retina. There is a clear variability in the clinical phenotypes of the novel sector RP mutations 
studied. M39R, for instance, initially shows a sector phenotype but over time the degenerative 
process spreads to the whole retina and the patient develops a classical RP phenotype. On the 
other hand, P23H, the most common autosomal dominant RP mutation, has been described to be 
heterogeneous, some people showed a sector phenotype and other people typical RP form, 
suggesting the influence of external factors (55). To date, most of the studies have focused on the 
idea that light is an important external factor underlying sector RP (56,57), and a different light 
distribution has been proposed in the different sections of the retina, based on a theoretical model 
(58). Previous reports on mice carrying a transgene with the P23H mutation involved housing the 
animals under overhead light or in the dark and higher photoreceptor degeneration was observed 
in the inferior retina of mice reared under an overhead light (59). Moreover, a recent study in X. 
Laevis  has provided further evidence of the effects of light on sector RP derived degeneration 
(60). In spite of these studies, no definitive answer has been provided about the link between light 
and sector RP, and it is not clear whether the direct action of light on Rh, or other unknown light-
sensitive factors located in the retina, may cause this particular phenotype. The detailed molecular 
basis of light-dependent translocation of proteins from the inner segment to the outer segment in 
photoreceptor cells, such as arrestin (61), or from the outer segment to the inner segment, like Gt 
(62), is still largely undeciphered, but appears to be a fine-regulated machine and a small change 
in one of the partners could significantly affect the function of others. Here, we show that N55K 
presents a different behavior upon illumination by forming a photointermediate unable to 
completely finish the retinal release process from its binding pocket. We suggest that this supports 
the direct action of light on Rh as the trigger for the observed sector phenotype. Thus, different 
times and/or dose exposures to light, in combination with malfunction of the receptor due to the 
mutation, may be the cause of sector RP. The mechanism could also indirectly involve other light-
sensitive proteins or factors so far unidentified, but confirming this aspect would require further 
investigation.  
In view of the clinical phenotypes observed for the two mutations reported herein, we can ask 
the question, is sector RP really that uncommon? Our results emphasize that sector RP etiology is 
not crystal clear. It could be that in many instances sector RP is an initial step, before the 
development of a typical RP phenotype. Some mutations might cause unnoticeable effects early in 
disease, and RP would be diagnosed as a typical form later on after severe visual impairment 
arises (52). For example, in one M39R family, the fundus of a son shows a sector phenotype (Fig. 
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2A), whereas his father (Fig. 2E) has a more typical RP form. Time will tell if the son will develop 
the typical form like his father or will remain as sector RP. According to our findings, we believe 
that the son will develop typical RP when older. In contrast, N55K appears relatively stable and 
restricted to the inferior retina in the families we have studied and the protein has unique properties 
upon illumination, suggesting this is genuine sector RP. 
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The abbreviations used are: DM, n-Dodecyl-D-Maltoside; ER, endoplasmic reticulum; 
FAF, fundus autofluorescence imaging; GPCR, G-protein-coupled receptor; Gt, 
transducin; MetaII, metarhodopsinII; OCT, Optical Coherence Tomography; PEI, 
polyethylenimine; PM, plasma membrane; Rh, rhodopsin; RP, retinitis pigmentosa; SB, 
Schiff base; TM, transmembrane.  
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FIGURE LEGENDS 
 
 
Figure 1. Representative fundus images from patients with RHO p.N55K. Color 
fundus images of patient GC18466 showing no progression from years 41 (A) to 45 
(B). (C-H) Autofluorescence images right (C, E, G) and left eyes (D, F, H) of GC18466 
13 years (C, D), GC16563 39 years (E, F) and GC18466 45 years (G, H). OCT images 
of GC18466 13 years left eye (I) and GC18466 45 years right eye (J). 
 
Figure 2. Representative images from patient with RHO p.M39R. Autofluorescence 
images, 55 degrees of field of six patients, each heterozygous for RHO, p.M39R 
presented in ascending age. (A) GC97/son, 28 years, (B) GC19172 29 years, (C) 
GC414 48 years; (D) GC109 50 years, (E) GC97/father 57 years, (F) GC4740 68 
years. Hyperfluorescent rings delineate normal retina in the two youngest individuals. 
 
Figure 3. The environment of positions M391.34 and N551.50 in dark-state and 
active (rhod)opsin crystal structures. A, B) Lateral (A) and extracellular (B) views of 
the proposed entry/exit channel for retinal between TMs 1 and 7, in the vicinity of 
M391.34. C) The polar cluster at the cytoplasmic side of TMs 1, 2 and 7 close to N551.50. 
Helices are displayed as cartoon, the relevant side-chains are shown as sticks colored 
by atom type and crystallographic water molecules as spheres. Dark-state crystal 
structures (PDB ids 1GZM, 1L9H and 1U19) are shown in orange and active-like 
structures (3DBQ, 2X72 and 3PQR) are in red. The side-chains of M/R39 (A, B) and 
N/K55 (C) are shown with a transparent surface. (hydroxyethyloxy)tri(ethyloxy)octane, 
palmitoyl and octyl glucoside (in A) and retinal molecules (in B) are shown with ball-
and-sticks. The image was created using PyMol (Schrodinger, LLC. The PyMOL 
Molecular Graphics System, Version 1.5). 
 
Figure 4. Subcellular localization of WT, and M39R and N55K mutants in SK-N-SH 
cells. (A and B) Representative images of rod opsin WT, M39R, N55K localization. SK-
N-SH cells were transfected with WT and mutant rod opsins and 24 h later, cells were 
fixed. (A) Rh-1D4 primary antibody (green) was used to compare localization with BiP 
(red) following cell permeabilization with Triton X100. (B) The Rh antibody to an 
extracellular epitope 4D2 was used on non-permeabilized cells to show traffic to the 
cell surface. Images were taken using a Carl Zeiss LSM 710 laser-scanning confocal 
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microscope. Scale bar=10μm.  (C) Quantification of opsin localization. Cells were 
scored for the predominant opsin localization at the PM (open bars) or overlap with an 
ER marker (grey bars) in approximately 400 cells. Error bars represent ± 2SE. (D) 
Western blot of WT, N55K and M39R transfected SK-N-SH cell lysates for rod opsin 
expression detected with Rh-1D4. 10 µg of soluble cell lysate protein (S) was 
compared to 10 µg of lysate digested with EndoH (E), or PNGase F (P). The asterisk 
(*) highlights the position of deglycosylated rod opsin and (**) the position of opsin 
dimer. ER retained opsin is sensitive to EndoH, whereas all opsin is sensitive to 
PNGase F and will tend to dimerize. The position of molecular weight markers is 
indicated on the left in kDa.  
 
Figure 5. UV-vis characterization for the immunopurified WT and RP mutant 
pigment. UV-vis spectra of WT (A), M39R (B) and N55K (C), in the basal state (—) 
and upon light stimulation (---) are shown. Spectra were recorded in buffer C at 20ºC. 
N55K mutant presents lower chromophoric band compared to WT, with a slightly blue-
shifted maximum (3 nm) according to UV-vis spectrophotometric measurements. Insets 
show the visible region for both dark and illuminated samples. 
 
Figure 6. Chemical and thermal stability for WT, and RP mutants. WT, M39R, and 
N55K in buffer C were treated with 50 mM hydroxylamine pH 7.0 at 20ºC for the 
chemical stability assay. Thermal stability assay was carried out at 48ºC. (A) Chemical 
reagent stability was determined by monitoring the decrease of  λmax over time (at 
498nm for WT and M39R, and at 495nm for N55K) (B) Thermal stability assay plot 
showing the decrease of absorbance at the at the λmax in the visible region over time. 
 
Figure 7. MetaII decay for WT and RP mutants. WT, M39R, and N55K in buffer C 
were illuminated and the Trp fluorescence increase at 330 nm was monitored in order 
to follow ligand release (38). After fluorescence stabilization, 50 mM Hydroxylamine pH 
7.0 was added to confirm complete retinal release. Fluorescence intensity spectra of 
MetaII decay for WT, M39R and N55K  are shown.  
 
Figure 8. Gt activation by WT and RP mutant opsin and Rh. WT and RP mutants 
opsin (open circles) and Rh (closed circles) activity were measured by means of a 
radionucleotide filter-binding assay in COS-1 cell membranes in buffer Gt. The mean 
and standard error of three independent measurements are represented.  
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Table 1: Spectroscopic properties of WT and RP mutants Rh. 
 a
The ratio of A280 /Amax, 
provides a measurement of sample purity and ability of opsin to form pigment with the 
chromophore. 
b
Thermal bleaching t½ values of purified samples in buffer C at 48ºC derived 
from the time course decay of the visible absorbance band at λmax.
 c
Hydroxylamine reactivity of 
the dark state pigments at 20ºC. Values were determined by monitoring the rate of λmax 
absorbance decrease after the addition of 50 mM hydroxylamine (pH 7.0) to the samples in 
buffer C and adjusted to a single exponential decay function for the N55K RP mutant or a linear 
function for WT and M39R. For a better comparison of initial velocity values, relative data are 
shown in parenthesis. 
d
MetaII stability t1⁄2 values were determined by fitting the experimental 
data to a single-exponential curve of Trp fluorescence increase, due to the retinal release at 20ºC 
(38).
 e
Gt activation initial rate was calculated as previously described (45). In all cases, mean 
values and standard error were obtained from three independent experiments.  
 
 
 
 
 
 
 
 
 
Rh WT M39R N55K 
Amax (dark) (nm) 498 498 495 
a
Ratio 
 
2.5 ± 0.1 6.0 ± 2.0  5.4 ± 0.3 
b
Thermal Stability (48ºC) (min) 26.5 ± 1.5 2.1 ± 0.3 2.1 ± 1.0 
c
Hydroxylamine 50 mM 
(20ºC) Initial Velocity (min
-1
) 
0.00036 ± 
0.00016 (1) 
0.00135 ± 0.0005 
(3.75) 
0.0181 ± 0.0045 
(50.2) 
d
MetaII Decay (20ºC) (min) 14.3 ±1.3 10.8 ± 0.5 14.7 ± 1.3 
e
Gt activation intial rate (min
-1
) 0.0875 ±0.0141 
(1) 
0.3± 0.03 (3.4) 0.0273 ± 0.0056 
(0.3) 
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